Montelukast does not affect exercise performance at subfreezing temperature in highly trained non-asthmatic endurance athletes

Anti-leukotriene therapy represents a new principle in asthma treatment. As elite athletes can have asthma, this double-blind, placebo-controlled, randomised cross-over study investigated the effect of 10 mg oral montelukast, a specific and potent cysteinyl leukotriene receptor antagonist, on physiological responses to submaximal and maximal aerobic exercise at -15 degrees C in 14 non-asthmatic highly trained endurance male athletes (maximal oxygen uptake [VO2 max] > 70 ml x kg(-1) x min(-1)). Heart rate, capillary blood lactate, minute ventilation with tidal volume and breathing frequency, respiratory exchange ratio and oxygen uptake were measured during the warm-up run of 10 min at 50%, runs of 10 min at 90% and 5 min at 80% VO2max, and a timed run to exhaustion. Spirometry was performed at baseline, at four hours after tablet ingestion, after warm-up and exercise at 80% VO2max, and in the post exercise period. Compared to placebo, montelukast did not increase baseline FEV1, have a beneficial effect on physiological performance variables, or increase the mean (SD) running time to exhaustion (montelukast: 332.3 [45.8] s, placebo: 340.1 [53.3] s, P = 0.22). These findings do not suggest the need for disallowing the use of this drug by asthmatic athletes.
© Copyright 2000 International Journal of Sports Medicine. Thieme. All rights reserved.

Bibliographic Details
Subjects:
Notations:endurance sports biological and medical sciences
Published in:International Journal of Sports Medicine
Language:English
Published: 2000
Online Access:https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-2000-3838
Volume:21
Issue:6
Pages:424-428
Document types:article
Level:advanced